IP Verse

Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters - EP3744326

EP3744326

JANSSEN PHARMACEUTICA
Application Number
EP20169861A
Filing Date
Mar 30, 2016
Status
Granted And Under Opposition
Nov 3, 2023
Grant Date
Dec 6, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2234617B2
EP4005555B1
EP4025188B1

Bibliography

The patent EP3744326B1 was granted to Janssen Pharmaceutica on Dec 6, 2023 following the initial filing on Mar 30, 2016 under the application number EP20169861A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ADVANZ PHARMA SERVICES UKSep 6, 2024ADMISSIBLE
APPLEYARD LEESSep 5, 2024ADMISSIBLE
HOFFMANN EITLESep 5, 2024ADMISSIBLE
STADA ARZNEIMITTELSep 5, 2024ADMISSIBLE
ELKINGTON AND FIFESep 4, 2024ADMISSIBLE
SANDOZSep 4, 2024ADMISSIBLE
STRAWMANSep 4, 2024ADMISSIBLE
ACCORD HEALTHCAREAug 28, 2024ADMISSIBLE
TEVA PHARMACEUTICALSAug 28, 2024ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents